CAR-T cell therapy clinical trial launched to treat advanced prostate cancer

Prostate cancer is one of the most common malignant tumors in menmCRPC is a very serious type of prostate cancer, and mCRPC patients continue to develop under androgen deprivation therapyFor these patients, standard androgen receptor (AR) targeted therapy has little effect and therefore has a very poor prognosisPSCA is a tumor-related antigen that is highly expressed in about 90% to 100% of primary and metastatic prostate cancersBecause of its better tissue specificity, the damage to normal tissue can be reduced by immunotherapyIt is also not susceptible to immune tolerance, so it is highly valued in the field of immunotherapy for prostate cancerStudies have shown that immunotherapy for PSCA is an effective way to treat advanced and hormone-dependent prostate cancer, which can inhibit tumor formation and growth, reduce metastasis and prolong patient survival through active and passive immunityCAR-T therapy is one of the breakthrough immunotherapies for cancer treatment, but progress has been slow in treating solid tumorsThis therapy involves collecting a sufficient number of T-cells from the patient's body and completing the editing of T-cells in vitro in a timely manner, enabling them to identify and attack specific cancer-causing proteins, such as PSCAWhen reintroduced into the patient's body, they can begin to destroy the target tumor cells"Developing CAR-T cell therapy for solid tumors is extremely challenging, requiring first reaching solid tumors and then working in complex microenvironments filled with cancer cells and other cells," said DrSaul Priceman, Associate Professor of Hematology and Hematopoietic Transplantation at The City of Hope"
patients with advanced prostate cancer urgently need a new treatment that can provide lasting remission," said DrTanya Dorff, lead researcher of the trial and head of the Hope City's Urology Cancer ProjectWe want to know if this treatment can treat prostate cancer, and we hope that this kind of cell therapy will be effective in improving the patient's condition"
References: s1 s City of Hope opens opens opens opens opens opens opens opens opens opens opens opens opens opens opens opens opens opens open smh.com.au(CAR) T cell for the prostate, from https:// , 2, psCA as a novel CAR T target for the https://